0HNC.L
BioMarin Pharmaceutical Inc.
LSEUSDEQUITY
DELAYED
Last price
66.68
▼ 1.21 (1.78%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
67.89
Day high
68.34
Day low
66.64
Volume
0
Market cap
—
P/E (TTM)
3.10
52W range
66.64 – 99.65
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 0HNC.L open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
667.83K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 2, 26 | HOMBACH ROBERT J. CPA Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | DERE WILLARD H Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | CLARK IAN THORNTON Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | WALBERT TIMOTHY P Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | HO MAYKIN Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | BODEM BARBARA W Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | ANDERSON ELIZABETH M Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | COUNTOURIOTIS ATHENA M Director |
STOCK | 7.49K | $0 | Direct |
| Jun 2, 26 | ENYEDY MARK J Director |
STOCK | 7.49K | $0 | Direct |
| May 7, 26 | FRIBERG GREGORY R Officer |
SELL | 3.28K | $176.68K | Direct |
| Mar 16, 26 | DAVIS GEORGE ERIC Officer |
STOCK | 14.57K | $0 | Direct |
| Mar 16, 26 | HARDY ALEXANDER Chief Executive Officer |
STOCK | 62.44K | $0 | Direct |
| Mar 16, 26 | HUBBARD CRISTIN Officer |
STOCK | 15.41K | $0 | Direct |
| Mar 16, 26 | FRIBERG GREGORY R Officer |
STOCK | 19.15K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ANDERSON ELIZABETH M |
Director | 41.94K | Stock Award(Grant) |
DAVIS GEORGE ERIC |
Officer | 79.83K | Stock Award(Grant) |
DERE WILLARD H |
Director | 46.44K | Stock Award(Grant) |
FRIBERG GREGORY R |
Officer | 51.82K | Sale |
GUYER CHARLES GREG |
Chief Technology Officer | 85.83K | Stock Award(Grant) |
HARDY ALEXANDER |
Chief Executive Officer | 218.89K | Stock Award(Grant) |
HOMBACH ROBERT J. CPA |
Director | 49.36K | Stock Award(Grant) |
HUBBARD CRISTIN |
Officer | 44.79K | Stock Award(Grant) |
MEIER RICHARD A |
Director | 126.93K | Stock Gift |
MUELLER BRIAN R |
Chief Financial Officer | 125.43K | Stock Award(Grant) |
Fundamentals
Market cap—
Enterprise value$16.24B
Revenue (TTM)$3.41B
Gross profit$1.74B
EBITDA$645.32M
Net income$72.97M
EPS (TTM)$0.22
Free cash flow$85.16M
Total cash$874.00M
Total debt$4.20B
Book value / share$32.66
Shares outstanding178.06M
Float192.39M
Short % of float—
Dividend yield—
Beta (5Y)0.23
Valuation & profitability ratios
Trailing P/E3.10
Forward P/E—
PEG ratio—
Price / sales—
Price / book2.04
EV / revenue4.77
EV / EBITDA25.16
Gross margin50.97%
Operating margin21.16%
Profit margin2.14%
Return on equity1.18%
Return on assets3.26%
Debt / equity66.47
Current ratio2.39
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $1.03B | +33.0% |
| Next quarter | — | — | $1.12B | +28.5% |
| Current year | — | — | $3.91B | +21.3% |
| Next year | — | — | $4.45B | +14.0% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.34%
Held by institutions103.75%
Institutions holding760
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
—
—
SMA 20
—
—
SMA 50
—
—
SMA 100
—
—
SMA 200
—
—
EMA 12
—
—
EMA 26
—
—
EMA 50
—
—
RSI (14)
—
—
MACD (12,26,9)
—
Hist —
ATR (14)
—
—
Realised vol 30D
—
Annualised
Bollinger upper
—
20, 2σ
Bollinger lower
—
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
—
—
Correlation to SPY
—
—
Realised vol 30D
—
Annualised
Market vol 1Y
—
SPY, annualised
Max drawdown 1Y
—
Peak to trough
Max drawdown 5Y
—
Peak to trough
ATR 14
—
Average true range
Beta (reported)
0.23
5Y monthly, from filing
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 26 | BMO Capital | INITIATED | Outperform | Outperform |
| Aug 18, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Aug 17, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Aug 17, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Aug 10, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| Aug 7, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| Aug 7, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| Jul 16, 26 | Citigroup | MAINTAINED | Buy | Buy |
| Jul 7, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| May 22, 26 | Canaccord Genuity | MAINTAINED | Buy | Buy |
| May 19, 26 | B of A Securities | MAINTAINED | Buy | Buy |
Headlines
City Chic Collective Ltd (ASX:CCX) (FY 2026) Earnings Call Highlights: EBITDA Soars 92% as ANZ ...
GuruFocus.com · 7m ago
Gtn Ltd (ASX:GTN) (FY 2026) Earnings Call Highlights: Cost Cuts and Cash Flow Surge Offset ...
GuruFocus.com · 7m ago
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Business Wire · 7m ago
Ampol Ltd (CTXAF) (H1 2026) Earnings Call Highlights: Record RCOP EBITDA of $1. ...
GuruFocus.com · 7m ago
Net Asset Value(s)
Business Wire · 7m ago
Navigator Global Investments Ltd (ASX:NGI) (FY 2026) Earnings Call Highlights: AUM Surges 21% ...
GuruFocus.com · 7m ago
Regis Healthcare Ltd (ASX:REG) (FY 2026) Earnings Call Highlights: Revenue Surges 16% to $1. ...
GuruFocus.com · 7m ago
Regal Partners Ltd (ASX:RPL) (H1 2026) Earnings Call Highlights: Record Flows and Doubled ...
GuruFocus.com · 7m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.